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Non-invasive therapeutic methods have recently been used in medical sciences. Enzymes
have shown high activity at very low concentrations in laboratories and pharmaceutical,
enabling them to play crucial roles in different biological phenomena related to living
organism, especially human medicine. Recently, using the therapeutic methods based on
non-invasive approaches has been emphasized in medical society. Researchers have
focused on producing medicines and tools reducing invasive procedures in medical.
Collagenases are proteins which catalyze chemical processes and break the peptide bonds
in collagen. Collagen may be generated more than the required amount or produced in
unsuitable sites or may not degrade after a certain time. In such cases, using an injectable
collagenase or its ointment can be helpful in collagen degradation. In both in vitro and
in vivo tests, it has been revealed that collagenases have several therapeutic properties in
wound healing, burns, nipple pain and some diseases including intervertebral disc her-
niation, keloid, cellulite, lipoma among others. This review describes the therapeutic
application of collagenase in medical sciences and the process for its production using
novel methods, paving the way for more effective and safe applications of collagenases.1. Introduction
Matrix metalloproteinases (MMPs) comprise a group of zinc
endopeptidases that have the ability to cleave the peptide bounds
in the extracellular matrix (ECM) [1]. Peptidase enzymes can
be divided into two groups: endopeptidase and exopeptidase.
Endopeptidases, which are the focus of the present review, are
divided into six major families, including metalloproteinase,
aspartic, serine, cysteine, glutamic and threonine peptidases [2]
(Figure 1). Most molecular structures of metalloproteases have
been shown to use zinc but some others require cobalt. There
are two subgroups of metalloproteinases, metalloexopeptidase
or metallocarboxypeptidase and metalloendopeptidases, which
include a disintegrin and metalloproteinase proteins and MMPs.MMPs can be comprised of collagenases (MMP-1, MMP-8,
MMP-13, and MMP-18) (Table 1), gelatinases (MMP-2 and
MMP-9), stromelysins (MMP-3, MMP-10, MMP-11, and MMP-
17), matrilysins (MMP-7 and MMP-26), membrane type (MMP-
14, MMP-15, MMP-16, MMP-24, and MMP-25) and other types
(MMP-12, MMP-19, MMP-20, MMP-21, MMP-22, MMP-28,
and MMP-29) [3]. Collagenase was identiﬁed for the ﬁrst time
in 1962 [4]. Collagenase as well as MMP-13 and MMP-18 are
the enzymes that break down four types of collagen (I, II, III, and
IV), and only protease enzymes are able to hydrolyze the triple-
helical domain of collagen under various physiological condi-
tions. Interstitial collagen ﬁbrils resist degradation by most pro-
teinase enzymes. Only MMP-1, MMP-2, and MMP-3 could start
the degradation of an intact, triple-helical collagen and of collagen
types I, II, and III into one- and three-quarter sections. MMP-1
and MMP-13 preferentially cleave collagen types II and III,
respectively [5], while collagenases have a covering that is a part
of substrate speciﬁcity. MMP-8, however, degrades type I
collagen three times more potently than MMP-1 or MMP-13.
After initial cleavage, ﬁbrillar collagen fragments become sus-
ceptible to further degradation by various MMPs such as MMP-2,
MMP-3, and MMP-9 [6]. At the moment when the collagen
is cleaved into smaller pieces, the endogenous enzymes helparticle under the CC BY-NC-ND license (http://
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Figure 1. Peptidase enzymes diagram.
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does not harm the cell membrane, it has been greatly used in
cell dispersion, tissue separation, and cell culture in laboratories
for many years. For instance, Clostridium histolyticum
(C. histolyticum) has been approved by the Food and Drug
Administration (FDA) as a drug that breaks down the tough
cords in Dupuytren and is widely used in human cell isolation,
wound healing [7], and wound debridement [8].
The data for isolation and characterization of three types of
collagenase enzymes from both microbial cells and animal tissues
are available. Pathogenicmicroorganisms, mainlyC. histolyticum,
have been reported as microbial collagenase resources [9]. These
collagenases could split each polypeptide chain of collagen into
multiple sites [10]. It is known that they function as an exotoxin
and disrupt connective tissue metabolism due to the hydrolysis
of collagen in the host cells [11]. The recombinant bacterial
collagenases are capable of hydrolyzing both water-insoluble
native collagens and water-soluble denatured collagens [12]. In
contrast to microbial collagenases that have been studied
with focus on a single species, tissue collagenases seem
more accessible to be isolated and characterized from a variety
of tissues in different animals. Since tissue collagenases
are digestive enzymes, they are commonly isolated from the
digestive tracts of various ﬁsh and invertebrates. Collagenase is
a unique enzyme used for the treatment of particular diseases,
and excessive collagen aggregation can induce disorder in the
etiology of organelles. Collagen is the major protein of the
extracellular ﬁlamentous tissues such as tendons, skin, cartilage,
and blood vessels, as well as the organic component of teeth,
bones, and the cornea. Recently, two types of collagenase have
been identiﬁed. The ﬁrst type of collagenase is synthesized by
some microorganisms. For example, C. histolyticum is a
bacterium that causes gas gangrene. It produces the collagenases
that can degrade the polypeptide chain of collagen over 200
states and hydrolyze the collagen in the c-terminal bonds. InTable 1
Classiﬁcation of collagenases and its substrates.
Row Enzyme Matrix metalloproteinase
1 Collagenase 1 MMP-1
2 Collagenase 2/Neutrophil
collagenase
MMP-8
3 Collagenases 3 MMP-13
4 Collagenases 4 MMP-18addition, it can denature the connective-tissue barriers of the or-
ganism. Hence, the biological process of connective tissues de-
pends on collagenase [13]. The second type of collagenase is
synthesized by mammals. It can break down collagen triple
helix from a certain point and make tropocollagens A and B,
which include 3/4, and 1/4 of tropocollagen molecules,
respectively. These broken fragments are then converted into
gelatin chains. In addition to the collagenase, physical factors
such as temperature can also separate tropocollagen polypeptide
chains and produce the gelatin chains, which can be degraded
by different proteases. One-third of the amino acid of collagen is
composed of glycine, proline and hydroxyproline. Unlike
mammal's collagenase, bacterial collagenase, which is one of the
factors of bacteria virulence, attacks the different parts of the
collagenal helix and breaks it down. Furthermore, there are
collagenases in the invasive strains of C. histolyticum and
Pseudomonas aeruginosa. Collagenases are more often used for
the separation of tissue cells in medical investigation. These
enzymes are successfully applied to remove and relocate the
insulin gland cells (for diabetic patients) [14]. Using
collagenases, one can also isolate intact liver parenchyma cells,
fat cells, and adrenal [15]. After being isolated, these cells can be
used for growing cells [16]. Collagenase has also been applied in
G-banding technique to study human chromosomes. Today,
collagenase has been employed as a treatment and seems to be
able to replace some invasive treatments for diseases, in which
excessive collagen deposition causes disorders in some
physiological functions of body systems [17,18].
Regarding the sequencing of nucleic acid and the functions of
protein, there are differences between the bacterial and vertebrate
collagenases. The most commonly used microbial collagenase in
medical products has been obtained from C. histolyticum [8–19].
Collagen forms one-third of the protein in the human body;
however, the change in its production or degradation can be a
source of problems. Collagen may be generated more than the
amount which is required or produced in unsuitable places, or not
degraded after the appropriate time. In such cases, the use of an
injectable form of collagenase or its ointment can be helpful in the
degradation of obstructive collagen. In the continuation of our
discussion, some human diseases that can be treated with colla-
genases are described.
2. Methodology
In the present review, we performed a literature search using
scientiﬁc sites such as ScienceDirect, Elsevier, Springer,
PubMed, and Google Scholar. The search comprised the key-
words collagenase, therapeutical, and disease. The referencesGroup Substrate
Collagenases Collagens 1, 3, 7, 8, 10, gelatin, L-selectin,
interleukin-1, entactin, ovostatin, MMP-2,
MMP-9, proteoglycans, aggrecan
Collagenases Collagens 1, 3, 5, 7, 8, 10, ﬁbronectin,
gelatin, aggrecan
Collagenases Collagens 1, 4, 9, 10, 14, ﬁbronectin,
MMP-9, gelatin, plasminogen, aggrecan,
perlecan osteonectin
Collagenases Type I collagen
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models or bio-assays used for examining the collagenase against
diseases. In this review, interest has been focused on experi-
mental studies performed on therapeutics.
3. Scientiﬁc evidence of collagenase therapeutic
applications
3.1. Dupuytren's disease
Dupuytren's disease is an abnormal thickening of the tissue
caused by the immoderate deposit of collagen tissue,mainly types I
and III. In this disorder, one ormoreﬁngers of the hands, especially
the small one, bent(s) into the palm and its function is reduced. The
disease, in many cases, happens to the old white men, and it is
likely a hereditary disease [20,21]. Collagenase fromC. histolyticum
source is a new cure for Dupuytren's muscle contraction, which
was approved by FDA [22]. Before production of C. histolyticum,
surgery operation was the only treatment for this disease [23]. To
evaluate the long-period efﬁcacy of collagenase C. histolyticum,
this method is very beneﬁcial to the patients [21]. Collagenase
injection is more efﬁcient than surgical fasciotomy [24], has less
and milder side effects and exhibits a better total reduction of
Dupuytren's contracture, which leads to higher patient
satisfaction [25]. In vitro studies on the inﬂuence of clostridial
collagenases on Dupuytren's cords [26] and on Dupuytren's
disease ﬁbroblasts [27] have demonstrated that Clostridium
collagenases can efﬁciently digest ECM of Dupuytren's disease
cords without inducing signiﬁcant cytotoxicity or structural
damage to non-collagenous tissue elements. Furthermore, it has
been indicated that Clostridium collagenases controlled cellular
spreading, attachment and proliferation [27].
3.2. Peyronie's disease
Peyronie's disease, known as induration penis plastica is
categorized as a connective tissue disorder that involves in the
growth of ﬁbrous plaques in the soft tissue of the penis, and it
affects 5% of men in the world [28,29]. The disease is caused by the
deposition of excessive collagen, in which the penis is tilted to one
side, damaged and failed to function properly. However, there are
some methods for treatment of this disorder. Collagenase
C. histolyticum, known as Xiaﬂex, is a drug approved by the
FDA for treatment of Dupuytren's contracture and as an
injectable medicine for treatment of Peyronie's disease. The
drug has been reported to work by breaking down the extra
collagen in the penis that causes Peyronie's disease [30].
3.3. Wound healing
Experimental investigations have shown that collagenase en-
zymes in the wound healing process can increase the proliferation,
the angiogenesis, and the migration of dermal cells [31].
Collagenase enzymes remove the living process of necrotic
tissues in the wound area but does not damage to the health
tissue. However, the formation of granulation and epithelial
cells are essential. Sometimes the healing process of bedsores
and colloidal scars is not carried out properly, and the wound
site becomes a suitable place for the growth of infectious agents.
In these situations, collagen must be reduced and controlled.
However, it is not easy to do this because collagen is not easilyaffected by proteases. In 2004, the value of Lucilia sericata
larvae in the treatment of wounds was recognized by both USA
FDA and the UK Prescription Pricing Authority so that sterile
maggots can now be ofﬁcially prescribed [32].3.4. Burns
Burns are an important public health problem in the world.
According to ofﬁcial statistics, 265000 deaths occur per year
due to burns alone [33]. Most deaths are caused by hot liquids,
steam, electrical burns, and other forms of burns that global
statistics are not available. Over 96% of fatal ﬁre-related burns
happen in low- and middle-income countries. In addition to
those who die, millions more are left with life-long disabilities
and deformity, often with resulting stigma and rejection [34].
Unlike serious burns, wound healing in partial-layer burn
wounds is treated with collagenase ointment [35]. Many people
are annually burned alive or died due to their injuries or
infections. The standard treatment of burned tissues by
collagenase has already been approved by the FDA [22].
Recently an investigation has indicated that collagenase
ointment heals burn wound faster than the standard treatment
of burns. In one study, 78 burn patients treated by collagenase
C. histolyticum ointment were compared to 41 patients whose
tissues around burn wounds were removed surgically [36]. The
use of collagenase provides a short-time hospitalization and
shortens the overall need for surgery and blood transfusions in
partial-layer burns. Therefore, collagenase can be considered as
the ﬁrst treatment option to remove scars in infants having a
partial-thickness burn wound without infection [37].3.5. Glaucoma
Glaucoma disease is the major reason for permanent blindness.
Approximately 60.5 million people suffered from this illness in
2010, with an estimated increase of about 79.6 million by 2020. To
control the disease, therapies that decrease intraocular pressure are
common, irrespective of the type of glaucoma. Collagenase injec-
tion is a method for treatment of glaucoma [38]. The use of
collagenase in the production of a drug helps to treat intraocular
scarring and ﬁbrosis that happen after glaucoma ﬁltration surgery
as well as after the implantation of set on implants. Glaucoma
occurs when the ﬂuid drainage channels of the eye are closed
because of abnormal production of collagen. Almost 40% of
blindness is caused by this disease. Using collagenase to treat
glaucoma was patented in 2013 [38].3.6. Intervertebral disc herniation
One of the factors in lowbackpain is the aggregation of collagen
tissue and the reduction in the distance between the vertebral spines.
Investigations have shown that injection of enzymes such as
collagenase can be an improvement in indications of disc herniation
[39,40]. Nowadays, more research is being performed on this issue
[39–41]. In a study by Zhang et al., 29 patients with perpetual low
back and sciatic pain were injected with intradiscal collagenase at
a single abnormal disk space. After conservative treatment for 2
months and resting for 2 weeks in bed, 6 patients (21%) obtained
complete pain relief, while 12 (42%), 6 (21%), and 1 patients got
noteworthy, moderate, and slight pain relief, respectively [39].
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Debridement is the elimination of unhealthy tissue from a
wound for improvement of healing. This procedure, which is a vital
factor in wound bed preparation, can be carried out by surgical,
chemical, mechanical, or autolytic removal of the tissue. In clinical
activities, various techniques are commonly used for debridement.
Many studies have conﬁrmed that collagenase is a safe and an
effective choice for debridement of cutaneous lesion and burn
wounds [42,43]. One of the most well-known applications of mi-
crobial collagenases in the health industry is related to the use of the
collagenase C. histolyticum in the enzymatic debridement of
wounds and other injuries, where the removal of devitalized tissue
is necessary [44]. Debridement is the removal of foreign material as
well as devitalized or contaminated tissue from a wound bed. This
process is applied to the treatment of pressure ulcers, leg ulcers,
wounds and burn wounds, and chronic, non-healing, or indolent
wounds considered to be stalled in the inﬂammatory phase of
wound healing [44]. Management of these chronic non-healing ul-
cers or wounds is a difﬁcult clinical problem [45], and the search for
effective therapeutics has been a key target for many years [46]. In
fact, enzymatic debridement has been suggested as a therapy more
than half a century ago and has been continuously applied till the
current days [47]. In several studies, enzymatic methods were
compared with surgical/mechanical methods as well as between
several enzymes. The results were controversial. Some studies
indicated that wound debridement is more effective than
enzymatic procedures [48] but others suggested that surgical
methods give faster results. However, enzymatic procedures
seem to be slightly more effective when the substrate is eschar as
opposed to ﬁbrin slough. The use of Clostridium collagenase is
considered as a capital gain in wound debridement. It helps to
avoid the complications of surgery and also limit the progress
and enlargement of the necrotic tissue. Enzymatic debridement
decreases the number of surgical debridement and the duration of
hospital stay [8,36,43,49–53].
3.8. Degradation of human retained placenta
In an experimental study, placenta samples were covered with
bacterial collagenase solution at several concentrations. Human
placenta and equine placenta collagens have themost sensitivity to
bacterial collagenase degradation. Average collagenase activity
found by the release of hydroxyproline (a major part of collagen)
from human was 1.6 times. However, in equine placenta, it was
three times greater than that of bovine. When injected into com-
plete placenta, the collagenase digested placenta smoothly within
6–12 h. Placenta was changed to liquid over night although um-
bilical blood vessels resisted bacterial collagenase degradation.
Bacterial collagenasewas highly effective in the decomposition of
human placenta collagen. Intraplacental injections of bacterial
collagenase via umbilical cord arteriesmay help to detach retained
placenta in women [54–58].
3.9. Cartilage repair
When using injectable collagenase to repair cartilage, a sig-
niﬁcant increase is occurred in chondrocyte cell compactness in
ulcer. Treatment with collagenase after preparing a high quality
puriﬁed enzyme caused cartilage repair, perhaps by increasing
the cell density at cartilage lesion edge. Therefore, to have abetter healing, surgical operation with the aim of promoting the
renovation of particular cartilage defects may be beneﬁcial
before treating with these enzymes [56–58].
3.10. Nipple pain
It has been well documented that breastfeeding has enormous
beneﬁts for both mother and baby; however, nipple pain is a
common cause reported by adult female for the early termination
of breastfeeding. Some studies have compared several treat-
ments that prevent or treat nipple pain [59,60]. One of these
treatments is the application of injectable bacterial collagenase
for treatment of nipple pain [61].
3.11. Keloid
Keloidal scar induces as the result of an excessive growth of
granulation tissue (collagen type 3) at the place of a cured skin
injury, which is not quickly substituted by collagen type 1.
Keloids are steady elastic lesions or bright stringy nodules that
can change their color from pink to red or dark brown. Keloids
should not be confused with hypertrophic scars, which are raised
scars that do not grow beyond the boundaries of the original
wound [62]. Collagenase pursuited by compression seems to be a
secure and decently effective care for keloid disease [63].
3.12. Vitrectomy
Another use of collagenase is the elimination of ﬁbroproli-
ferative tissue in speciﬁc vitrectomy cases. It has been deter-
mined that satisfactorily puriﬁed collagenase can create
extensive degrade of scar tissue after a 10-, 15- or 30-
minute incubation. There has been no phenotypic damage to
scar cellular sections or to the internal restricting membrane of
the retina [64]. A 45-minute exposure of retinas before damaged
by photocoagulation to collagenase enzyme also did not result in
morphologic witness of injury [65,66].
3.13. Cellulite
Cellulite or adiposis edematosa is the hernia of subcutaneous
fat within ﬁbrous connective tissue that indicates skin dimpling,
and the symptoms often are on the pelvic region, lower limbs,
and abdomen [67]. Cellulite occurs in most sexually mature
females [68]. Bacterial collagenase is an effective enzyme for
the treatment of cellulite.
3.14. Chronic total occlusions (CTO)
Clostridial collagenases have been used for the treatment of
CTO in non-humanmodels [69]. CTO is a coronary problem [70]. It
includes a lot of degrees of ﬁbroma, atheromatous emboli, and
thrombus, relies on the blockage handle and its time period and
it happens in nearly 30% of the patients with this disease. CTO
is usually used to be cured by surgery or less regularly
percutaneous intervention. In most cases, despite the ischemia
upraises using percutaneous intervention as a treatment for
CTO, surgery is preferred. However, percutaneous intervention
is limited for inability to cross the CTO with leader wires
because of the attendance of occlusive ﬁbrotic plaques [69]. The
combination of percutaneous intervention with collagenolytic
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tissue is the major structural ingredient of atherosclerotic
plaques and the use of a collagenolytic enzyme to the plaques
prior to leader wire crossings results in plaque breakdown and
therefore to a signiﬁcant 2-fold betterment [71]. Clinical trials of
collagenase have currently revealed that in human manners,
application of topical delivery of collagenase enzyme into
coronary whole occlusion is possible and safe [72]. However,
more clinical trials are still necessary to prove exactly the
efﬁcacy of this technique in humans; the result is very promising.
3.15. Gene delivery
Recently, collagenases have been used in genetic therapy.
Actually, the simplest and safest technique for gene delivery can be
the implementing of decorated nucleic acids into cells and tissues
[73]. However, gene therapy technique suffers from one
disadvantage, which is the low efﬁciency of gene expression [74].
Macromolecules, such as monoclonal antibodies and DNA
vectors, broadly show low activity in solid neoplasm for gene
therapy [75]. The application of collagenase (puriﬁed or mixed
with hyaluronidase) indicates transfection efﬁciency in the
spreading of metastases, particularly in abnormal swelling of any
part of the body with a high segment of ECM [76]. It has also
been proved that this method is effective in the bony muscle and
liver tissue [77], wherein in addition to a raise in the transfection
ratio, it causes an increase in the transfection homogeneity [77].
3.16. Uterine ﬁbroid
A uterine ﬁbroid is a leiomyoma that is secreted from the ﬂat
muscle layer of the uterus. The disease is often multifarious, and
if the uterus contains too many leiomyomata to count, it is
mentioned as propagate uterine leiomyomatosis. Having
approved by FDA as a drug that does not inﬂuence nervous
system or blood vessels, C. histolyticum collagenase has been
evaluated as a suitable treatment for this disease [78]. Diversity of
collagen types and amounts within personal ﬁbroids can lead to
various reactions and require supplementary investigations. The
injection of C. histolyticum collagenase has potential to be used
for the treatment of ﬁbroids [79].
4. Conclusions
Therapeutic methods based on non-invasive approaches have
recently been emphasized inmedical community.Researchers have
focused on producing medicines and tools that reduce invasive
procedures in medical practice. Enzymes have important capacity
in pharmaceuticals activities due to their highly selective character
and high speciﬁc at very low concentrations. True collagenases
cleave helical regions of collagen molecules in ﬁbrillar form under
various physiological conditions of pH and temperature. However,
it is known that gelatin and the non-helical regions of collagen
molecules could be degraded by numerous mammalian proteases,
including pepsin, trypsin, chymotrypsin, papain, and other tissue
enzymes. The study of collagenases started at the end of last cen-
tury, followed by the isolation of an extracellular enzyme, namely
Clostridium and then by identiﬁcation and characterization of a
number of other collagenases of both bacterial and mammalian
origin. Until recently, the production of true collagenases by bac-
teria has been considered to be conﬁned to only a few species [19–37]such as clostridia and a small number of other organisms, notably a
strain of Vibrio alginolyticus (formerly Achromobacter iophagus).
Unlike animal collagenases enzyme that split collagen in its native
triple-helical structure [80], collagenases from bacteria differ from
those of vertebrates, which demonstrate broader substrate
speciﬁcity [81]. Regarding its recently proposed application,
collagenase enzyme appears to be a convenient and a cheap
medication for the treatment of burns, wound healing, and some
other diseases in near future. However, it seems to be produced
and used as a drug in clinics due to gaps in data and needs for
further research. In the current review, all available and relevant
published papers pertaining to therapeutic application of
collagenase in human diseases were used. Human diseases and
collagenases have been the center of this review, while role of
collagenases in the treatment of more speciﬁc diseases that
excessive collagen deposition is the main problem were
emphasized [1,2]. Furthermore, collagenases can be applied in the
isolation of liver parenchymal as well as fat and adrenal intact
animal cells [5,6] and in cell culture after their separation. To sum
up, this review describes the therapeutic application of
collagenase in medical sciences and the process for its production
using novel methods, which paves a way for more effective and
safe applications of collagenases. There are some hope that future
investigations can develop methods and processes to produce
collagenase with new origins such as Lucilia sericata, which is
non-pathogenic and very important to wound healing.
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